The DOI matches its Crossref record; 92 of the 92 references it cites were found in a registry or an index.
Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway
Open accessAbstract
Eradicating tumor dormancy that develops following epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) treatment of EGFR-mutant non-small cell lung cancer, is an attractive therapeutic strategy but the mechanisms governing this process are poorly understood. Blockade of ERK1/2 reactivation following EGFR TKI treatment by combined EGFR/MEK inhibition uncovers cells that survive by entering a senescence-like dormant state characterized by high YAP/TEAD activity. YAP/TEAD engage the epithelial-to-mesenchymal transition transcription factor SLUG to directly repress pro-apoptotic BMF, limiting drug-induced apoptosis. Pharmacological co-inhibition of YAP and TEAD, or genetic deletion of YAP1, all deplete dormant cells by enhancing EGFR/MEK inhibition-induced apoptosis. Enhancing the initial efficacy of targeted therapies could ultimately lead to prolonged treatment responses in cancer patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Particularly, YAP/TAZ plays a crucial role in the intrinsic and acquired resistance to inhibitors targeting RTK/MAPK pathway (24, 28–32).”
From YAP/TAZ mediates resistance to KRAS inhibitors through inhibiting proapoptosis and activating the SLC7A5/mTOR axis (2024) · cites this paper as [29]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“accumulating evidence suggests that the dysregulation of the Hippo-YAP/TAZ pathway serves as a central resistance mechanism in multiple therapies, particularly in the intrinsic and acquired resistance to RTK, RAF, or MEK inhibitors (24, 28, 29).”
From YAP/TAZ mediates resistance to KRAS inhibitors through inhibiting proapoptosis and activating the SLC7A5/mTOR axis (2024) · cites this paper as [29]
Experimental — accuracy not yet measuredIn the citing paper
“the authors observed that after treatment with the combination of EGFR and MEK inhibitors, the vast majority of barcodes were unique, suggesting that the ability of cells to enter dormancy following dual inhibition of EGFR and MEK is predominately driven by a stochastic process [56].”
From Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer (2021) · cites this paper as [56]
In the citing paper
“The results revealed a large fraction of shared barcodes within the cells treated with EGFR inhibitor alone, consistent with selection of pre-existing persister clones.”
From Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer (2021) · cites this paper as [56]
In the citing paper
“Meanwhile, other studies suggest that some persister phenotypes arise via plasticity induced by drug treatment [56,64,65].”
From Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer (2021) · cites this paper as [56]
In the citing paper
“Kurppa et al. observed that combined EGFR/MEK inhibition of EGFR-mutant NSCLC model cells selected a population of dormant drug-tolerant cells exhibiting senescence-like features characterized by high YAP/TEAD activity [56].”
From Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer (2021) · cites this paper as [56]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
Model-based Analysis of ChIP-Seq (MACS)
Zhang, Y., Liu, T., Meyer, C. A., Eeckhoute, J., Johnson, D. S., Bernstein, B. E., Nusbaum, C., Myers, R. M., Brown, M., Li, W., et al. (2008) · Genome Biology · doi:10.1186/gb-2008-9-9-r137 · Cited by 18,386
The Molecular Signatures Database Hallmark Gene Set Collection
Liberzon, A., Birger, C., Thorvaldsdóttir, H., Ghandi, M., Mesirov, J. P., & Tamayo, P. (2015) · Cell Systems · doi:10.1016/j.cels.2015.12.004 · Cited by 13,807
Heinz, S., Benner, C., Spann, N., Bertolino, E., Lin, Y. C., Laslo, P., Cheng, J. X., Murre, C., Singh, H., & Glass, C. K. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.05.004 · Cited by 13,382
Integrating single-cell transcriptomic data across different conditions, technologies, and species
Butler, A., Hoffman, P., Smibert, P., Papalexi, E., & Satija, R. (2018) · Nature Biotechnology · doi:10.1038/nbt.4096 · Cited by 13,174
Fast and accurate long-read alignment with Burrows-Wheeler transform.
Li, H., & Durbin, R. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btp698 · Cited by 12,063
QuPath: Open source software for digital pathology image analysis
Bankhead, P., Loughrey, M. B., Fernández, J. A., Dombrowski, Y., McArt, D. G., Dunne, P. D., McQuaid, S., Gray, R. T., Murray, L. J., Coleman, H. G., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-17204-5 · Cited by 8,908
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
deepTools2: a next generation web server for deep-sequencing data analysis
Ramírez, F., Ryan, D. P., Grüning, B., Bhardwaj, V., Kilpert, F., Richter, A. S., Heyne, S., Dündar, F., & Manke, T. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw257 · Cited by 8,096
Scenic: single-cell regulatory network inference and clustering.
Aibar, S., González-Blas, C. B., Moerman, T., Huynh-Thu, V. A., Imrichova, H., Hulselmans, G., Rambow, F., Marine, J.-C., Geurts, P., Aerts, J., et al. (2017) · Nature Methods · doi:10.1038/nmeth.4463 · Cited by 6,520
Flagged first, then by citations
Cited by
Sorted by citations
Targeting the Hippo pathway in cancer, fibrosis, wound healing and regenerative medicine
Dey, A., Varelas, X., & Guan, K.-L. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0070-z · Cited by 860
Regulated cell death (RCD) in cancer: key pathways and targeted therapies
Peng, F., Liao, M., Qin, R., Zhu, S., Peng, C. Y., Fu, L., Chen, Y., & Han, B. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01110-y · Cited by 895
Rational combinations of targeted cancer therapies: background, advances and challenges
Jin, H., Wang, L., & Bernards, R. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00615-z · Cited by 503
Persistent Cancer Cells: The Deadly Survivors
Shen, S., Vagner, S., & Robert, C. (2020) · Cell · doi:10.1016/j.cell.2020.10.027 · Cited by 320
Lung cancer in patients who have never smoked — an emerging disease
LoPiccolo, J., Gusev, A., Christiani, D. C., & Janne, P. A. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00844-0 · Cited by 320
Emerging role of tumor cell plasticity in modifying therapeutic response
Qin, S., Jiang, J., Lü, Y., Nice, E. C., Huang, C., Zhang, J., & He, W. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00313-5 · Cited by 289
YAP/TAZ as master regulators in cancer: modulation, function and therapeutic approaches
Piccolo, S., Panciera, T., Contessotto, P., & Cordenonsi, M. (2022) · Nature Cancer · doi:10.1038/s43018-022-00473-z · Cited by 264
The Hippo Pathway in Liver Homeostasis and Pathophysiology
Driskill, J. H., & Pan, D. (2020) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-030420-105050 · Cited by 236
Insights into recent findings and clinical application of YAP and TAZ in cancer
Franklin, J. M., Wu, Z., & Guan, K.-L. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-023-00579-1 · Cited by 213
Hagenbeek, T. J., Zbieg, J. R., Hafner, M., Mroue, R., Lacap, J. A., Sodir, N. M., Noland, C. L., Afghani, S., Kishore, A., Bhat, K. P., et al. (2023) · Nature Cancer · doi:10.1038/s43018-023-00577-0 · Cited by 215
Mikubo, M., Inoue, Y., Liu, G., & Tsao, M. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.07.017 · Cited by 218
Rational Cancer Treatment Combinations: An Urgent Clinical Need
Boshuizen, J., & Peeper, D. S. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.05.031 · Cited by 221
Cancer drug-tolerant persister cells: from biological questions to clinical opportunities
Russo, M., Chen, M., Mariella, E., Peng, H., Rehman, S. K., Sancho, E., Sogari, A., Toh, T. S., Balaban, N. Q., Batlle, E., et al. (2024) · Nature Reviews Cancer · doi:10.1038/s41568-024-00737-z · Cited by 210
Cell–matrix interface regulates dormancy in human colon cancer stem cells
Ohta, Y., Fujii, M., Takahashi, S., Takano, A., Nanki, K., Matano, M., Hanyu, H., Saito, M. K., Shimokawa, M., Nishikori, S., et al. (2022) · Nature · doi:10.1038/s41586-022-05043-y · Cited by 219
Hippo signalling in the liver: role in development, regeneration and disease
Russell, J. O., & Camargo, F. D. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00571-w · Cited by 211
Self-citationTransferrin receptor targeting chimeras for membrane protein degradation
Zhang, D., Duque-Jimenez, J., Facchinetti, F., Brixi, G., Rhee, K., Feng, W. W., Janne, P. A., & Zhou, X. X. (2024) · Nature · doi:10.1038/s41586-024-07947-3 · Cited by 210
Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer
Cabanos, H. F., & Hata, A. N. (2021) · Cancers · doi:10.3390/cancers13112666 · Cited by 189
MEK inhibitor resistance mechanisms and recent developments in combination trials
Kun, E., Tsang, Y. T. M., Ng, C. W., Gershenson, D. M., & Wong, K. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102137 · Cited by 198
Self-citationDrug-tolerant persister cells in cancer: the cutting edges and future directions
Pu, Y., Li, L., Peng, H., Liu, L., Heymann, D., Robert, C., Vallette, F. M., & Shen, S. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00815-5 · Cited by 189
Apoptosis in Cancer Biology and Therapy
Moyer, A. F., Tanaka, K., & Cheng, E. H. Y. (2025) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-051222-115023 · Cited by 212
Nilsson, M. B., Sun, H., Robichaux, J., Pfeifer, M., McDermott, U., Travers, J., Diao, L., Xi, Y., Tong, P., Shen, L., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aaz4589 · Cited by 177
Pearson, J. D., Huang, K., Pacal, M., McCurdy, S. R., Lü, S., Aubry, A., Yu, T., Wadosky, K. M., Zhang, L., Wang, T., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.06.016 · Cited by 178
Li, Y., Chen, H., Xie, X., Yang, B., Wang, X., Zhang, J., Qiao, T., Guan, J., Qiu, Y., Huang, Y., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-2370 · Cited by 177
Tanaka, K., Yu, H. A., Yang, S., Han, S., Selçuklu, S. D., Kim, K., Ramani, S., Ganesan, Y. T., Moyer, A. F., Sinha, S., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.07.006 · Cited by 169
Self-citationControl of stem cell renewal and fate by YAP and TAZ
Driskill, J. H., & Pan, D. (2023) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-023-00644-5 · Cited by 173
Chapeau, E. A., Sansregret, L., Galli, G. G., Chêne, P., Wartmann, M., Mourikis, T. P., Jaaks, P., Baltschukat, S., Barbosa, I. A. M., Bauer, D., et al. (2024) · Nature Cancer · doi:10.1038/s43018-024-00754-9 · Cited by 168
Therapeutic targeting of TEAD transcription factors in cancer
Pobbati, A. V., Kumar, R., Rubin, B. P., & Hong, W. (2023) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2022.12.005 · Cited by 147
Pharmacological blockade of TEAD–YAP reveals its therapeutic limitation in cancer cells
Sun, Y., Hu, L., Tao, Z., Jarugumilli, G. K., Erb, H., Singh, A., Li, Q., Cotton, J. L., Greninger, P., Egan, R. K., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34559-0 · Cited by 145
When dormancy fuels tumour relapse
Santos-de-Frutos, K., & Djouder, N. (2021) · Communications Biology · doi:10.1038/s42003-021-02257-0 · Cited by 153
Tao, S., Huang, J., Gao, Y., Li, Z., Wei, Z., Dawes, H., & Guo, S. (2021) · Bioactive Materials · doi:10.1016/j.bioactmat.2021.04.031 · Cited by 136
Self-citationHe, J., Qiu, Z., Fan, J., Xie, X., Sheng, Q., & Sui, X. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01891-4 · Cited by 134
Senolytics for Cancer Therapy: Is All that Glitters Really Gold?
Carpenter, V. J., Saleh, T., & Gewirtz, D. A. (2021) · Cancers · doi:10.3390/cancers13040723 · Cited by 124
Clonal architecture in mesothelioma is prognostic and shapes the tumour microenvironment
Zhang, M., Luo, J., Sun, Q., Harber, J., Dawson, A. G., Nakas, A., Busacca, S., Sharkey, A. J., Waller, D. A., Sheaff, M. T., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21798-w · Cited by 120
Cellular senescence: Neither irreversible nor reversible
Reimann, M., Lee, S., & Schmitt, C. A. (2024) · The Journal of Experimental Medicine · doi:10.1084/jem.20232136 · Cited by 125
de Miguel, F. J., Gentile, C., Feng, W. W., Silva, S. J., Sankar, A., Expósito, F., Cai, W. L., Melnick, M. A., Robles-Oteíza, C., Hinkley, M. M., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.07.005 · Cited by 117
Elamin, Y. Y., Robichaux, J. P., Carter, B. W., Altan, M., Tran, H. T., Gibbons, D. L., Heeke, S., Fossella, F. V., Lam, V. K. L., Le, X., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.06.006 · Cited by 112
Sun, T., & Chi, J. (2020) · Genes & Diseases · doi:10.1016/j.gendis.2020.05.004 · Cited by 111
Haderk, F., Chou, Y., Čech, L., Fernández-Méndez, C., Yu, J. X., Olivas, V. R., Meraz, I. M., Rabago, D. B., Kerr, D. L., Gómez, C. F., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47423-0 · Cited by 108
Linke, J. A., Munn, L. L., & Jain, R. K. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00745-z · Cited by 109
Reita, D., Pabst, L., Pencreach, E., Guérin, É., Dano, L., Rimelen, V., Voegeli, A., Vallat, L. D., Mascaux, C., & Beau‐Faller, M. (2021) · Cancers · doi:10.3390/cancers13194926 · Cited by 107
Tanaka, Y., Chiwaki, F., Kojima, S., Kawazu, M., Komatsu, M., Ueno, T., Inoue, S., Sekine, S., Matsusaki, K., Matsushita, H., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00240-6 · Cited by 107
A Potential Role of YAP/TAZ in the Interplay Between Metastasis and Metabolic Alterations
Yamaguchi, H., & Taouk, G. M. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00928 · Cited by 106
Hypoxia-driven intratumor heterogeneity and immune evasion
Terry, S., Engelsen, A. S. T., Buart, S., El‐Sayed, W., Venkatesh, G. H., & Chouaı̈b, S. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.07.004 · Cited by 102
Kashima, Y., Shibahara, D., Suzuki, A., Muto, K., Kobayashi, I. S., Plotnick, D. O., Udagawa, H., Izumi, H., Shibata, Y., Tanaka, K., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-2811 · Cited by 102
Tuning Cancer Fate: Tumor Microenvironment's Role in Cancer Stem Cell Quiescence and Reawakening
Sistigu, A., Musella, M., Galassi, C., Vitale, I., & Maria, R. D. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.02166 · Cited by 102
Gogleva, A. A., Polychronopoulos, D., Pfeifer, M., Poroshin, V., Ughetto, M., Martin, M. J., Thorpe, H., Bornot, A., Smith, P. D., Sidders, B. S., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29292-7 · Cited by 95
Adachi, Y., Kimura, R., Hirade, K., Yanase, S., Nishioka, Y., Kasuga, N., Yamaguchi, R., & Ebi, H. (2023) · Nature Cancer · doi:10.1038/s43018-023-00575-2 · Cited by 93
Novel insights from a multiomics dissection of the Hayflick limit
Chan, M., Yuan, H., Soifer, I., Maile, T. M., Wang, R. Y., Ireland, A., O'Brien, J. J., Goudeau, J., Chan, L. J., Vijay, T., et al. (2022) · eLife · doi:10.7554/elife.70283 · Cited by 99
“Next, we retrieved a gene set of YAP1/TEAD1 targets assembled by Kurrpa et al. from five separate studies ( Kurppa et al., 2020 ).”
InfluentialChhouri, H., Alexandre, D., & Grumolato, L. (2023) · Cancers · doi:10.3390/cancers15020504 · Cited by 103
Expected and unexpected effects after systemic inhibition of Hippo transcriptional output in cancer
Baroja, I., Kyriakidis, N. C., Halder, G. A., & Moya, I. M. (2024) · Nature Communications · doi:10.1038/s41467-024-46531-1 · Cited by 96
Tissue factor is a critical regulator of radiation therapy-induced glioblastoma remodeling
Jeon, H.-M., Kim, J., Cho, H. J., Lee, W. J., Nguyen, D., Kim, S. S., Oh, Y. T., Kim, H., Jung, C., Piñero, G., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.06.007 · Cited by 91
Cell plasticity in cancer cell populations
Shen, S., & Clairambault, J. (2020) · F1000Research · doi:10.12688/f1000research.24803.1 · Cited by 91
Transcription factors in fibroblast plasticity and CAF heterogeneity
Melchionna, R., Trono, P., Carlo, A. D., Modugno, F. D., & Nisticò, P. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02934-4 · Cited by 92
Haikala, H. M., Lopez, T., Köhler, J., Eser, P. O., Xu, M., Zeng, Q., Teceno, T. J., Ngo, K., Zhao, Y., Ivanova, E. V., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-2426 · Cited by 85
Self-citationTackling Osimertinib Resistance in EGFR-Mutant Non–Small Cell Lung Cancer
Blaquier, J. B., Ortiz‐Cuaran, S., Ricciuti, B., Mezquita, L., Cardona, A. F., & Recondo, G. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1912 · Cited by 82
The Crosstalk between Src and Hippo/YAP Signaling Pathways in Non-Small Cell Lung Cancer (NSCLC)
Hsu, P., Yang, C., Jablons, D. M., & You, L. (2020) · Cancers · doi:10.3390/cancers12061361 · Cited by 85
Nie, M., Chen, N., Pang, H., Jiang, T., Jiang, W., Tian, P., Yao, L., Chen, Y., DeBerardinis, R. J., Li, W., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci160152 · Cited by 83
YAP/TEAD inhibitor VT3989 in solid tumors: a phase 1/2 trial
Yap, T. A., Kwiatkowski, D. J., Dagogo‐Jack, I., Offin, M. D., Zauderer, M. G., Kratzke, R. A., Desai, J., Body, A. L., Millward, M., Tolcher, A. W., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-04029-3 · Cited by 91
YAP and β-Catenin Cooperate to Drive Oncogenesis in Basal Breast Cancer
Quinn, H. M., Vogel, R., Popp, O., Mertins, P., Lan, L., Messerschmidt, C., Landshammer, A., Lisek, K., Château‐Joubert, S., Marangoni, E., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-2801 · Cited by 83
Understanding Drug Sensitivity and Tackling Resistance in Cancer
Tyner, J. W., Haderk, F., Kumaraswamy, A., Baughn, L. B., Ness, B. V., Liu, S., Marathe, H., Alumkal, J. J., Bivona, T. G., Chan, K. S., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-3695 · Cited by 81
Genomic hallmarks and therapeutic implications of G0 cell cycle arrest in cancer
Wiecek, A. J., Cutty, S. J., Kornai, D., Parreno-Centeno, M., Gourmet, L. E., Tagliazucchi, G. M., Jacobson, D. H., Zhang, P., Xiong, L., Bond, G. L., et al. (2023) · Genome biology · doi:10.1186/s13059-023-02963-4 · Cited by 83
Alveolar Differentiation Drives Resistance to KRAS Inhibition in Lung Adenocarcinoma
Li, Z., Zhuang, X., Pan, C.-H., Yan, Y., Thummalapalli, R., Hallin, J., Torborg, S., Singhal, A., Chang, J. C., Manchado, E., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0289 · Cited by 74
Dormant cancer cells: programmed quiescence, senescence, or both?
Truskowski, K., Amend, S. R., & Pienta, K. J. (2023) · Cancer and Metastasis Reviews · doi:10.1007/s10555-022-10073-z · Cited by 87
Brägelmann, J., Lorenz, C., Borchmann, S., Nishii, K., Wegner, J., Meder, L., Ostendorp, J., Ast, D., Heimsoeth, A., Nakasuka, T., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25728-8 · Cited by 79
Moghal, N., Li, Q., Stewart, E., Navab, R., Mikubo, M., D’Arcangelo, E., Martins-Filho, S. N., Raghavan, V., Pham, N., Li, M., et al. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2022.12.003 · Cited by 74
Dormancy, stemness, and therapy resistance: interconnected players in cancer evolution
Francescangeli, F., Angelis, M. L. D., Rossi, R., Cuccu, A., Giuliani, A., Maria, R. D., & Zeuner, A. (2023) · Cancer and Metastasis Reviews · doi:10.1007/s10555-023-10092-4 · Cited by 80
Recent Therapeutic Approaches to Modulate the Hippo Pathway in Oncology and Regenerative Medicine
Barry, E., Simov, V., Valtingojer, I., & Venier, O. (2021) · Cells · doi:10.3390/cells10102715 · Cited by 73
Cellular Dormancy in Cancer: Mechanisms and Potential Targeting Strategies
Min, H.-Y., & Lee, H. (2023) · Cancer Research and Treatment · doi:10.4143/crt.2023.468 · Cited by 78
Theard, P. L., Sheffels, E., Sealover, N. E., Linke, A. J., Pratico, D. J., & Kortum, R. L. (2020) · eLife · doi:10.7554/elife.58204 · Cited by 69
AKT and EZH2 inhibitors kill TNBCs by hijacking mechanisms of involution
Schade, A. E., Perurena, N., Yang, Y., Rodriguez, C. L., Krishnan, A., Gardner, A., Loi, P., Xu, Y., Nguyen, V. T. M., Mastellone, G. M., et al. (2024) · Nature · doi:10.1038/s41586-024-08031-6 · Cited by 72
Self-citationEGFR Regulates the Hippo pathway by promoting the tyrosine phosphorylation of MOB1
Ando, T., Arang, N., Wang, Z., Costea, D. E., Feng, X., Goto, Y., Izumi, H., Gilardi, M., Ando, K., & Gutkind, J. S. (2021) · Communications Biology · doi:10.1038/s42003-021-02744-4 · Cited by 67
Akkoç, Y., Peker, N., Akçay, A., & Gözüaçık, D. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.627023 · Cited by 71
Covalent disruptor of YAP-TEAD association suppresses defective Hippo signaling
Fan, M., Lu, W., Che, J., Kwiatkowski, N. P., Gao, Y., Seo, H.-S., Ficarro, S. B., Gokhale, P. C., Liu, Y., Geffken, E. A., et al. (2022) · eLife · doi:10.7554/elife.78810 · Cited by 68
Self-citationTargeting the Hippo pathway in cancer
Harvey, K. F., & Tang, T. T.-L. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01234-0 · Cited by 68
Zhao, J., Xu, W., Zhou, F., Zhang, X., Zhou, M., Miao, D., Yu, L., Zhang, Y., Fan, J., Zhou, C., et al. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01085-z · Cited by 68
Context-dependent roles of YAP/TAZ in stem cell fates and cancer
LeBlanc, L., Ramirez, N., & Kim, J. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-021-03781-2 · Cited by 72
Noia, V. D., D’Aveni, A., D’Argento, E., Rossi, S., Ghirardelli, P., Bortolotti, L., Vavassori, V., Bria, E., & Ceresoli, G. L. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100280 · Cited by 60
New Insights into YAP/TAZ-TEAD-Mediated Gene Regulation and Biological Processes in Cancer
Zhao, Y., Sheldon, M., Sun, Y., & Ma, L. (2023) · Cancers · doi:10.3390/cancers15235497 · Cited by 63
Stewart, C. A., Gay, C. M., Ramkumar, K., Cargill, K. R., Cardnell, R. J., Nilsson, M. B., Heeke, S., Park, E. M., Kundu, S. T., Diao, L., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.07.002 · Cited by 85
Criscione, S. W., Martin, M. J., Oien, D. B., Gorthi, A., Miragaia, R. J., Zhang, J., Chen, H., Karl, D. L., Mendler, K., Markovets, A. A., et al. (2022) · npj Precision Oncology · doi:10.1038/s41698-022-00337-w · Cited by 57
Targeted therapy and drug resistance in thyroid cancer
Zhang, Y., Xing, Z., Liu, T., Tang, M., Mi, L., Zhu, J., Wu, W., & Wei, T. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114500 · Cited by 55
Chen, R., Qian, Z., Xu, X., Zhang, C., Niu, Y., Wang, Z., Sun, J., Zhang, X., & Yu, Y. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105442 · Cited by 54
Liu, S., Jiang, A., Tang, F., Duan, M., & Li, B. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02323-9 · Cited by 60
Wang, Y., Liu, L., Song, Y., Yu, X., & Deng, H. (2022) · Protein & Cell · doi:10.1007/s13238-021-00894-z · Cited by 50
Structure-Based Design of Y-Shaped Covalent TEAD Inhibitors
Lu, W., Fan, M., Ji, W., Tse, J., You, I., Ficarro, S. B., Tavares, I., Che, J., Kim, A. Y., Zhu, X., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01548 · Cited by 52
Self-citationProtein-Protein Interaction Disruptors of the YAP/TAZ-TEAD Transcriptional Complex
Pobbati, A. V., & Rubin, B. P. (2020) · Molecules · doi:10.3390/molecules25246001 · Cited by 55
Progress with YAP/TAZ-TEAD inhibitors: a patent review (2018-present)
Zagiel, B., Melnyk, P., & Cotelle, P. (2022) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2022.2096436 · Cited by 50
Biomolecular condensates: hubs of Hippo-YAP/TAZ signaling in cancer
Kiang, K. M. Y., Ahad, L., Zhong, X., & Lu, Q. R. (2024) · Trends in Cell Biology · doi:10.1016/j.tcb.2024.04.009 · Cited by 56
Targeting Hippo signaling in cancer: novel perspectives and therapeutic potential
Lv, L., & Zhou, X. (2023) · MedComm · doi:10.1002/mco2.375 · Cited by 46
Alsaed, B., Lin, L., Son, J., Li, J., Smolander, J., Lopez, T., Eser, P. Ö., Ogino, A., Ambrogio, C., Eum, Y., et al. (2025) · Nature Communications · doi:10.1038/s41467-024-55378-5 · Cited by 51
Self-citationThinking Differently about Cancer Treatment Regimens
Settleman, J., Neto, J. M. F., & Bernards, R. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1187 · Cited by 52
Liu, W., Jin, W., Zhu, S., Chen, Y., & Liu, B. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.10.011 · Cited by 50
Hippo Signaling at the Hallmarks of Cancer and Drug Resistance
Kumar, R., & Hong, W. (2024) · Cells · doi:10.3390/cells13070564 · Cited by 47
GABRP sustains the stemness of triple-negative breast cancer cells through EGFR signaling
Li, X., Wang, H., Yang, X., Wang, X., Zhao, L., Zou, L., Yang, Q., Hou, Z., Tan, J., Zhang, H., et al. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.04.028 · Cited by 46
Self-citationThe Hallmarks of Cancer as Ecologically Driven Phenotypes
Somarelli, J. A. (2021) · Frontiers in Ecology and Evolution · doi:10.3389/fevo.2021.661583 · Cited by 46
Coregulation of pathways in lung cancer patients with EGFR mutation: therapeutic opportunities
Rosell, R., Cardona, A. F., Arrieta, O. G., Aguilar, A., Ito, M., Pedraz‐Valdunciel, C., Codony‐Servat, J., & Santarpía, M. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01519-2 · Cited by 48
Hu, L., Sun, Y., Liu, S., Erb, H., Singh, A., Mao, J., Luo, X., & Wu, X. (2022) · eLife · doi:10.7554/elife.80210 · Cited by 49
Role Of YAP Signaling in Regulation of Programmed Cell Death and Drug Resistance in Cancer
Zhou, W., Lim, A., Edderkaoui, M., Osipov, A., Wu, H., Wang, Q., & Pandol, S. J. (2023) · International Journal of Biological Sciences · doi:10.7150/ijbs.83586 · Cited by 49
Pfeifer, M., Brammeld, J. S., Price, S., Pilling, J. E., Bhavsar, D., Farcas, A. M., Bateson, J., Sundarrajan, A., Miragaia, R. J., Guan, N., et al. (2024) · Communications Biology · doi:10.1038/s42003-024-06190-w · Cited by 43
Mechanosensitive genomic enhancers potentiate the cellular response to matrix stiffness
Cosgrove, B. D., Bounds, L. R., Taylor, C. K., Su, A. L., Rizzo, A. J., Barrera, A., Sun, T., Safi, A., Song, L., Whitlow, T. J., et al. (2025) · Science · doi:10.1126/science.adl1988 · Cited by 43
Metadata
- Authors
- Kurppa, K. J., Liu, Y., To, C., Zhang, T., Fan, M., Vajdi, A., Knelson, E. H., Xie, Y., Lim, K., Cejas, P., Portell, A., Lizotte, P. H., Ficarro, S. B., Li, S., Chen, T., Haikala, H. M., Wang, H., Bahcall, M., Gao, Y., Shalhout, S., Boettcher, S., Shin, B. H., Thai, T., Wilkens, M. K., Tillgren, M. L., Mushajiang, M., Xu, M., Choi, J., Bertram, A. A., Ebert, B. L., Beroukhim, R., Bandopadhayay, P., Awad, M. M., Gokhale, P. C., Kirschmeier, P. T., Marto, J. A., Camargo, F. D., Haq, R., Paweletz, C. P., Wong, K.-K., Barbie, D. A., Long, H. W., Gray, N. S., & Jänne, P. A.
- Affiliations
- Harvard University (US)
- Dana-Farber Cancer Institute (US)
- Brigham and Women's Hospital (US)
- NYU Langone Health (US)
- Tongji University (CN)
- Boston Children's Hospital (US)
- Broad Institute (US)
- ORCID
- Kurppa, Kari J.
- Liu, Yao
- To, Ciric
- Zhang, Tinghu
- Fan, Mengyang
- Vajdi, Amir
- Knelson, Erik H.
- Xie, Yingtian
- Lim, Klothilda
- Cejas, Paloma
- Portell, Andrew
- Lizotte, Patrick H.
- Ficarro, Scott B.
- Li, Shuai
- Chen, Ting
- Haikala, Heidi M.
- Wang, Haiyun
- Bahcall, Magda
- Gao, Yang
- Shalhout, Sophia
- Boettcher, Steffen
- Shin, Bo Hee
- Thai, Tran
- Wilkens, Margaret K.
- Xu, Man
- Choi, Jihyun
- Bertram, Arrien A.
- Ebert, Benjamin L.
- Beroukhim, Rameen
- Bandopadhayay, Pratiti
- Awad, Mark M.
- Gokhale, Prafulla C.
- Marto, Jarrod A.
- Camargo, Fernando D.
- Haq, Rizwan
- Paweletz, Cloud P.
- Wong, Kwok-Kin
- Barbie, David A.
- Long, Henry W.
- Gray, Nathanael S.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2020-01
- Volume
- 37
- Issue
- 1
- Pages
- 104-122.e12
- ISSN
- 1535-6108 (ISSN-L)
- PMC
- PMC7146079
- OpenAlex
- W3000285141
- Cited by
- 475
- References
- 92
- Citations by year
- 2026: 50 · 2025: 94 · 2024: 82 · 2023: 81 · 2022: 71 · 2021: 65 · 2020: 30
- FWCI
- 30.92
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Cancer Cell (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- UTUPub (University of Turku) (submittedVersion)
- Funders
- National Cancer Institute (NIH 5 P30 CA06516, R01CA135257, R35CA220497)
- Novartis Institutes for BioMedical Research
- Bristol-Myers Squibb
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
- Eli Lilly and Company
- Daiichi Sankyo Company
- Astellas Pharma US
- Dana-Farber/Harvard Cancer Center
- American Cancer Society (CRP-17-111-01-CDD)
- Takeda Oncology
- Massachusetts Institute of Technology
- Instrumentariumin Tiedesäätiö
- Takeda Pharmaceuticals U.S.A.
- National Science Foundation (P300PB_161026/1, P400PM_183862)
- Dana-Farber Cancer Institute
- National Institutes of Health (CA233800, R01 CA222218)
- Jane ja Aatos Erkon Säätiö
- Novartis
- Krebsliga Schweiz (KLS-3625-02 2015)
- Sanofi
- Orionin Tutkimussäätiö
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Hippo pathway signaling and YAP/TAZ
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- tumor dormancy, EGFR tyrosine kinase inhibitors, EGFR-mutant non-small cell lung cancer, MEK inhibition, Slug, BMF, apoptosis, transcriptional reprogramming, drug resistance
- MeSH terms
- YAP-Signaling Proteins, Animals, Cell Survival, Female, Humans, Lung Neoplasms, Male, Mutation, Transcription Factors, Transcription, Genetic, Signal Transduction, Gene Expression Regulation, Neoplastic, Cellular Senescence, Apoptosis, Gene Deletion, Mice, Knockout, Cell Cycle Proteins, Drug Resistance, Neoplasm, Cell Line, Tumor, MAP Kinase Kinase 1, Adaptor Proteins, Signal Transducing, Cell Proliferation, Mice, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
